OSL Shares OncoSil Medical Limited

WATCH ASX · ASX

$0.75 +7.14% Prices as of close 2026-10-27

Regulatory decision for its targeted radiotherapy platform could unlock substantial value.

Signal breakdown

▸FDA HDE application review is a major catalyst.
▾Below 50-day MA (-19.11%)

Is OSL a buy right now?

Trend: OSL is trading below the 50-day average (-18.48%), RSI 39 — neutral momentum, with a 3-month return of -32.43%.

Valuation & quality: OncoSil Medical Limited trades on forward P/E -0.0, price-to-book 4.63; fundamentals show net margin -213.4%, return on equity -268.2%, revenue growth 248.1% year on year.

Our screen: WATCH (score 0) — Regulatory decision for its targeted radiotherapy platform could unlock substantial value.

Computed from end-of-day data; not personal advice.

12-month price chart

Daily close, 2026-02-08 → 2026-10-27 (AUD). Range 0.39 – 1.54.

Monthly returns

Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	Oct 26
-21.50%	-3.90%	+4.10%	+39.20%	+63.40%	-0.90%	-24.30%	-13.80%

Fundamentals

Market cap

$27.5M

P/E (ttm)

-0.0

Forward P/E

-0.0

EPS (ttm)

$-0.48

Price / book

4.63

Beta

1.31

Net margin

-213.4%

ROE

-268.2%

Revenue growth

248.1%

Revenue (ttm)

$5.1M

Free cash flow

$-6,297,035

Debt / equity

52-wk range

$0.37 – $1.64

Volume

14,682

Avg volume (3m)

137,292

Technical signals

RSI (14)

38.6

vs 50-day MA

-18.48%

1-mo return

-12.79%

3-mo return

-32.43%

Volume z-score

-0.64

About OncoSil Medical Limited

OncoSil Medical Limited, a medical device company, develops and commercializes localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.

Sector: Healthcare · Industry: Medical Devices · Australia · Website

Related Biotech picks

CSL.AXCSL Limited MSB.AXMesoblast Limited IMR.AXImricor Medical System SLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren Pharmaceuticals DXB.AXDimerix Limited NYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.